Geoffrey McDonough takes the role, joining the firm from Genzyme
Geoffrey McDonough, currently Genzyme’s president of Europe, Middle East and Africa (EMEA), will move Swedish Orphan Biovitrum (Sobi) as president and ceo on 15 August. He will succeed Kennet Rooth, who has been acting ceo since the beginning of the year.
McDonough has held several leading positions within Genzyme in the US since 2002, beginning his career with the firm in corporate development.
‘Geoff is well-recognised for his solid and broad commercial and clinical expertise and for his background in the orphan drug and niche speciality market,’ said Bo Jesper Hansen, chairman of Sobi.
‘He will lead Sobi toward our vision of becoming the leading niche speciality pharmaceutical company in Europe.’